The Effect of Citrate Dialysate on Clot Formation and Anemia in Hemodialysis Patients

Overview

Acetate-free citrate containing dialysate is expected to be clinically effective in maintaining hemodynamic stability during hemodialysis (HD). It has been demonstrated that citrate dialysate help produce a local anticoagulant effect by chelating ionized calcium. Moreover, citrate can improve phosphate and beta2 macroglobulin and better control of arterial hypertension and hemoglobinemia. We therefore would like to study the effect of citrate dialysate on clot formation and anemia while reducing heparin in chronic hemodialysis patients.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 30, 2017

Detailed Description

This is the prospective comparison study. This study enrolled chronic hemodialysis patients age more than 18 who undergo hemodialysis 3 times per week for at least 3 months. All the patients should have serum ferritin 200-1000 ng/L and TSAT of 15-50%. The investigators exclude patients with age more than 70 years, comorbidities influencing citrate metabolism (hepatic failure,liver transplantation,cancer with bone metastasis), patients using heparin free protocol, hyperkalemia worsened by hypocalcemia, contraindication to heparin, treatment with cinacalcet or oral anticoagulant, patients using central venous catheter with blood flow less than 300 ml/min, and patients using low molecular weight heparin. The study will be conducted in three phases over a period of 4 months. After run-in period for 2 weeks using acetate dialysate, the heparin dose will be titrated to lowest effective dose. During the first phase, citrate was replaced for acetate and heparin will be reduced to 50%. The second and third phase will be performed by reducing heparin doses to 25 % and heparin free consecutively. Each phase lasts for 4 weeks. Washout period for 2 weeks will be alternated after each phase. Data collection: The investigators measure blood chemistries such as CBC, BUN creatinine electrolytes calcium phosphorus and KT/V at the beginning and at the end of each session. Ionized calcium will be monitored pre and post dialysis in each session. In addition, the investigators record clot score and erythropoietin dosage in each session and each phase.

Interventions

  • Device: Citrate dialysate
    • Change form acetate to citrate dialysate

Arms, Groups and Cohorts

  • Experimental: Citrate arm
    • Citrate dialysate Phase 1 : Reduce heparin to 50% Phase 2: Reduce heparin to 25% Phase 3: Heparin free

Clinical Trial Outcome Measures

Primary Measures

  • Effect of citrate dialysate to anemia
    • Time Frame: 3 months
    • Hemoglobin in gram per dL

Secondary Measures

  • Effect of citrate dialysate to dialyzer clotting
    • Time Frame: 3 months
    • clot score.The clot score ranges from 1-4.Score 1 means no residual blood or less than 10 % in the fibers Score 2 means residual blood in < 10-25% of the fiber score 3 means residual blood in 25-50 % of the fiber Score 4 means more than 50 % of the fiber Score3
  • effect of citrate dialysate to electrolyte changes
    • Time Frame: 3 months
    • electrolyte in mmoll/L(Sodium,Potassium,Chloride and bicarbonate)
  • effect of citrate dialysate to dialysis adequacy
    • Time Frame: 3 months
    • Kt/V

Participating in This Clinical Trial

Inclusion Criteria

  • This study enrolled chronic hemodialysis patients age more than 18 who undergo hemodialysis 3 times per week for at least 3 months. – Serum ferritin 200-1000 ng/L and TSAT of 15-50%. Exclusion Criteria:

  • age more than 70 years, – comorbidities influencing citrate metabolism (hepatic failure,liver transplantation,cancer with bone metastasis), – patients using heparin free protocol,hyperkalemia worsened by hypocalcemia – contraindication to heparin, – treatment with cinacalcet, or oral anticoagulant – patients using central venous catheter with blood flow less than 300 ml/min – patients using low molecular weight heparin

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Bangkok Metropolitan Administration Medical College and Vajira Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Thananda Trakarnvanich, Associate Professor – Bangkok Metropolitan Administration Medical College and Vajira Hospital
  • Overall Official(s)
    • Thananda Trakarnvanich, MD, Principal Investigator, Faculty of Medicine,Vajira Hospital,Navamindradhiraj University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.